Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

22 May 2025 07:00

RNS Number : 6675J
Sabre Insurance Group PLC
22 May 2025
 

Sabre Insurance Group plc

Trading Update

Active optimisation of premium growth and profit through the cycle

 

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading motor insurance underwriters, today provides an update on trading for the period from 1 January 2025 to 30 April 2025 ahead of its Annual General Meeting ("AGM") later this morning.

Unaudited

Unaudited

 

4 months ended

4 months ended

 

 30 Apr 2025

 30 Apr 2024

Gross written premium - Motor Vehicle

£58.1m

£77.1m

Gross written premium - Motorcycle

£3.3m

£3.5m

Gross written premium - Taxi

£4.7m

£5.1m

Gross written premium - Total

£66.1m

£85.7m

Business highlights for the first four months of 2025

‒ Good premium volume being written in the first four months of the year against historic norms

‒ Total gross written premium of £66.1m up over 8% on the prior 5-year average of £61.0m for the same period. Core Motor Vehicle gross written premium of £58.1m over 7% up on the prior 5-year average of £54.2m for the same period

‒ Comparator period in Q1 2024 was a period of extraordinary growth

‒ Long-term commitment to profit over volume underpins our approach to managing Sabre through the cycle

‒ Loss ratio remains in-line with target

‒ Post-dividend solvency capital ratio well above the Group's last reported figure of 171.1% at 31 December 2024 reflecting strong profitability year-to-date

‒ Successful launch of Sabre Direct Motorcycle product, expanding distribution and strengthening our presence in the Motorcycle market

‒ Good progress towards enhanced pricing infrastructure with testing planned for H2 2025

Market trends

‒ Market pricing data suggests that decreases have flattened across the Motor Vehicle market

‒ Anticipate market premium increases later in 2025 in response to 12-month market price reductions of c.15%, set against continued high levels of inflation

‒ Claims inflation for 2025 anticipated to remain at high single-digits as previously guided

Full-year guidance reiterated

‒ Outlook for the full-year and delivering on our 2030 targets is underpinned by a commitment to profit over volume

‒ Anticipate good profit and dividends in 2025 despite weak market conditions in the year to date

‒ Undiscounted net insurance margin expected to be within our target 18% to 22% range

‒ Premium growth for the remainder of 2025 dependent on market conditions. Current expectation of a slight decrease in total premium year-on-year

‒ On-track to deliver our target of at least £80m of profit before tax in 2030

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"I am pleased that Sabre remains on track to deliver target margins and strong profit for the year, despite the relatively weak pricing environment that we have seen in 2025 to date. We have managed the insurance cycle in line with our successful long-term strategy and have reduced the volume of business written during this less attractive period. It is worth noting that our reported premium for this period compares the peak of the previous cycle against the weakest part of the current pricing cycle.

We have, however, continued to write healthy levels of business at strong margins and are very well positioned to return to growth when pricing inevitably corrects. Maintaining pricing discipline means that we are confident of delivering strong profitability and a good dividend this year.

The Sabre Direct Motorcycle product has now launched, thanks to a terrific effort by our team. We are currently writing a limited amount of premium as we move through our initial "test and learn" phase.

We have also progressed development of our enhanced pricing infrastructure, which is integral to the next stage of our Ambition 2030 plan. This remains on-track for testing later this year and is expected to begin positively impacting the top-line later, in 2026.

Overall, the Group is performing well through this current period of market weakness and will be in a position of strength, ready to grow the core motor book, and accelerate the development of our motorcycle product. We remain on-track to deliver our target of at least £80m of profit before tax in 2030".

 

Investor enquiries

01306 747 272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Teneo

sabre@teneo.com

James Macey White / Ffion Dash

 

LEI Code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEDFMFEISEFI
Date   Source Headline
25th May 20237:01 amRNSBoard Appointment
25th May 20237:00 amRNSTrading Update
11th May 202311:42 amRNSDirector/PDMR Shareholding
18th Apr 20233:19 pmRNSDirector/PDMR Shareholding
12th Apr 202311:53 amRNSDirector/PDMR Shareholding
6th Apr 202312:28 pmRNSDirector/PDMR Shareholding
31st Mar 20233:43 pmRNSNotice of AGM
31st Mar 20233:37 pmRNSDirector/PDMR Shareholding
14th Mar 20237:00 amRNSFinal Results
13th Mar 202312:13 pmRNSDirector/PDMR Shareholding
13th Feb 20231:51 pmRNSDirector/PDMR Shareholding
13th Jan 20231:52 pmRNSHolding(s) in Company
11th Jan 20234:00 pmRNSDirector/PDMR Shareholding
19th Dec 20222:31 pmRNSHolding(s) in Company
13th Dec 20221:20 pmRNSDirector/PDMR Shareholding
11th Nov 202212:09 pmRNSDirector/PDMR Shareholding
7th Nov 20221:47 pmRNSHolding(s) in Company
13th Oct 20227:00 amRNSTrading Update
11th Oct 20223:20 pmRNSDirector/PDMR Shareholding
28th Sep 20222:11 pmRNSDirector/PDMR Shareholding
23rd Sep 202211:47 amRNSDirector/PDMR Shareholding
13th Sep 20223:57 pmRNSDirector/PDMR Shareholding
26th Aug 202210:45 amRNSDirectorate Change
11th Aug 20223:25 pmRNSDirector/PDMR Shareholding
10th Aug 20229:08 amRNSHolding(s) in Company
1st Aug 20229:19 amRNSDirector/PDMR Shareholding
28th Jul 20222:34 pmRNSHolding(s) in Company
28th Jul 20229:14 amRNSHolding(s) in Company
27th Jul 20221:35 pmRNSDirector/PDMR Shareholding
27th Jul 20229:26 amRNSHolding(s) in Company
27th Jul 20229:19 amRNSDirector/PDMR Shareholding
26th Jul 202212:19 pmRNSDirector/PDMR Shareholding
26th Jul 202212:06 pmRNSDirector/PDMR Shareholding
26th Jul 20227:00 amRNSHalf-Year Report 2022
18th Jul 20221:07 pmRNSHolding(s) in Company
14th Jul 20227:00 amRNSHalf-Year 2022 Trading Update
12th Jul 202212:49 pmRNSDirector/PDMR Shareholding
1st Jul 20229:55 amRNSHolding(s) in Company
14th Jun 202211:58 amRNSDirector/PDMR Shareholding
13th Jun 20223:54 pmRNSDirector/PDMR Shareholding
6th Jun 20223:15 pmRNSDirector/PDMR Shareholding
6th Jun 20223:06 pmRNSDirector/PDMR Shareholding
25th May 20221:24 pmRNSResult of AGM
25th May 20227:00 amRNSTrading Update
19th May 20221:45 pmRNSHolding(s) in Company
13th May 20222:24 pmRNSHolding(s) in Company
11th May 20222:27 pmRNSDirector/PDMR Shareholding
26th Apr 20223:17 pmRNSDirector/PDMR Shareholding
26th Apr 20222:21 pmRNSDirector/PDMR Shareholding
14th Apr 20229:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.